Effectiveness and safety of apixaban versus warfarin in obese patients with nonvalvular atrial fibrillation enrolled in medicare and veteran affairs

Prof. Deitelzweig shares us some of his recent research on health economics and outcomes research on real world data.

PRADA Trial: Prevention Of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: Long-term Follow-up Of A 2 X 2 Factorial, Randomized, Placebo-controlled, Double-blind Clinical Trial Of Candesartan And Metoprolol

Dr. Geeta Gulati, Dr. Siri Lagethon Heck and Prof. Torbjorn Omland  presenting the new result from PRADA Trial.

ADAPTABLE Study: Aspirin Dosing: A Patient-centric Trial Assessing Benefits And Long-term Effectiveness Trial

Prof. William Schuyler Jones speaks about the results of the ADAPTABLE Study.

PARADISE-MI: Prospective Arni Versus Ace Inhibitor Trial To Determine Superiority In Reducing Heart Failure Events After Myocardial Infarction

Prof. Marc Pfeffer presenting the new result from PARADISE-MI.

Inspiration-S Double Blind Randomized Controlled Trial: Atorvastatin Versus Placebo In Critically-ill Patients With Covid-19

Dr. Behnood Bikdeli speaks about his study, that looked at statins from a diffrent direction, even as a preventive way.

Core Knowledge in Action: The Ultimate Guide to Lipids

Prof. Eugene Yang, the chair of the ACC cardiovascular disease session share with us some guidance and principles from the recent ACC 2021 session that focuses on the ultimate guide to lipids.

Evolocumab use in patients with human immunodeficiency virus and dyslipidemia

Franck Boccara speaks about his study, the efficacy and tolerability of evolocumab a new PCSK9 inhibitors in specific populations such as the HIV population.

Tailor-Pci Randomized Clinical Trial Follow-up Study: Effect Of Genotype-guided Oral P2y12 Inhibitors Vs Conventional Clopidogrel On Long-term Ischemic Outcomes After Percutaneous Coronary Intervention

Prof. Naveen L. Pereira speaks about how we can individualize, personalize cardiology treatment.

Results From the Twilight Study: Sex-Specific Outcomes In High-Risk Patients Receiving Ticagrelor With Or Without Aspirin After Percutaneous Coronary Intervention

Dr. Birgit Vogel speaks about the newest findings of the Twilight Study.

VOYAGER PAD Trial: Reductions In Total Ischemic Events With Rivaroxaban In Patients With Symptomatic Pad After Revascularization

Prof.  Rupert Bauersachs speaks about the newest findings of the VOYAGER PAD Trial.

Aspirin Vs. Clopidogrel During Chronic Maintenance Monotherapy After Percutaneous Coronary Intervention

Prof. Hyo-Soo Kim summarized the most important findings of the trial.

Effects Of Interleukin-6 Inhibition With Ziltivekimab On Biomarkers Of Inflammation Among Patients At High Risk For Atherosclerotic Events

Professor Paul M. Ridker summarize what we learned about the connection between inflammation and atherosclerosis in the last couple of years.

ISCHEMIA Trial: Impact Of Completeness Of Revascularization On Clinical Outcomes In Patients With Stable Ischemic Heart Disease Treated With An Invasive Vs. Conservative Strategy

Prof. Gregg Stone summarize the findings of ISCHEMIA Trial.

A Phase 2 Trial Of The Efficacy And Safety Of Evinacumab In Patients With Severe Hypertriglyceridemia

Prof. Robert Rosenson summarize the main findings of the trial.

Hypertension Guidelines: Do They Vary Across the World as Much as My Blood Pressure Has Today

Prof. Paul Whelton speaks about the newest guidelines in the treatment of Hypertension.

STRENGTH Trial: Relationship Between Omega-3 Fatty Acid Levels And Major Adverse Cardiovascular Outcomes In Patients With High Cardiovascular Risk

Prof. Steven E. Nissen summarize the main findings of the STRENGTH Trial.

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients.

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

HOPE 4 - Impact on cardiovascular risk of a community based multifaceted intervention in individuals with hypertension in 2 middle income countries: The Heart Outcomes Prevention and Evaluation 4 study

SYNTAXES: Ten-Year Survival after Coronary Artery Bypass Grafting versus Percutaneous Coronary Intervention: The SYNTAX Extended Survival study

MITRA-FR - 2 years follow-Up of the MITRA-FR study a randomized controlled trial evaluating the effectiveness of percutaneous mitral valve repair in secondary mitral regurgitation

DAPA HF The Dapagliflozin And Prevention Of Adverse-outcomes In Heart Failure Trial

CONDI-2/ERIC-PPCI Effect of remote ischemic conditioning on clinical outcomes in patients with Stsegment elevation myocardial infarction undergoing primary percutaneous coronary intervention